Preferred Label : Rituximab and Hyaluronidase Human;
NCIt synonyms : Rituximab Plus Hyaluronidase; Rituximab/Hyaluronidase; Rituximab/Hyaluronidase Human;
NCIt definition : A combination preparation of rituximab, a genetically engineered chimeric murine/human
immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen,
and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity.
Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase
reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue.
This increases the permeability of the subcutaneous tissue and enhances the absorption
of rituximab into the systemic circulation. In turn, rituximab targets and binds to
CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the
induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated
cytotoxicity (ADCC). When administered subcutaneously, hyaluronidase, an endoglycosidase,
increases the dispersion and absorption of co-administered drugs. CD20 is expressed
on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety
of B-cell malignancies.;
Drug name : Rituxan Hycela;
NCI Metathesaurus CUI : CL524655;
Codes from synonyms : 447;
Origin ID : C136821;
UMLS CUI : C4490298;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
